Novavax Global Commercial Operations and COVID-19 Vaccine Update

Adolescent study expansion of US/Mexico Phase 3 Pre-Crossover Post-Crossover N = 2,247 R Adolescents 2:1 12-<18 y/o novavax 5 μg antigen + 5 μg 50 μα Matrix-M antigen + 50 μα Matrix-M Placebo Placebo 5 μg 5 μg Placebo Placebo antigen + 50 μg Matrix-M antigen + 50 μα Matrix-M Blinded Crossover PREVENT-19 PRE-fusion Protein Subunit Vaccine Efficacy Novavax Trial | COVID-19 5 μg antigen + 50 μg Matrix-M Day 0 Day 21 Injection 1 Injection 2 Day 0 Injection 1 Day 21 Injection 2 Booster © 2023 NOVAVAX. All rights reserved. 36 36

View entire presentation